Evidence map›Paper›PMID 38569183›Full record

ArticleCancer research2024

Mathematical Model-Driven Deep Learning Enables Personalized Adaptive Therapy.

Kit Gallagher, Maximilian A R Strobl, Derek S Park, Fabian C Spoendlin, Robert A Gatenby, Philip K Maini, Alexander R A Anderson

Erratum issuedAbstract read
In one paragraph

Article in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Article
  2. AI-based augmentation of oncology clinical trials.Nature reviews. Clinical oncology · 2026
    Review
  3. Article
  4. Hazard curvature makes within-host variability costly for survival.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Stochastic Evolutionary Control in Heterogeneous Populations.bioRxiv : the preprint server for biology · 2026
    Article
  11. Article
  12. The future of mathematical oncology in the age of AI.NPJ systems biology and applications · 2026
    Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Kit Gallagher *Wolfson Centre for Mathematical Biology, Mathematical Institute, Oxford, United Kingdom.ORCID 0000-0003-1401-115X
Maximilian A R Strobl *Integrated Mathematical Oncology, Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0003-4484-8823
Derek S ParkIntegrated Mathematical Oncology, Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0001-5164-4285
Fabian C SpoendlinWolfson Centre for Mathematical Biology, Mathematical Institute, Oxford, United Kingdom.ORCID 0000-0002-3006-6217
Robert A GatenbyIntegrated Mathematical Oncology, Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0002-1621-1510
Philip K Maini *Wolfson Centre for Mathematical Biology, Mathematical Institute, Oxford, United Kingdom.ORCID 0000-0002-0146-9164
Alexander R A Anderson *Integrated Mathematical Oncology, Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0002-2536-4383

Funding

The Delta Ecology of NSCLC TreatmentU54CA274507 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI Joel Brown · 2023 to 2026
$9.4M
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and ResistanceU01CA232382 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI ANDERSON, ALEXANDER ROBERTSON ALLAN, ANTONIA, SCOTT J. · 2018 to 2022
$3.3M
Engineering and Physical Sciences Research Council (EPSRC) EP/S024093/1National Cancer Institute (NCI) U01CA232382National Cancer Institute (NCI) U54CA274507NCI NIH HHS U01 CA232382NCI NIH HHS U54 CA274507
6 · The paper itself

Abstract

Standard-of-care treatment regimens have long been designed for maximal cell killing, yet these strategies often fail when applied to metastatic cancers due to the emergence of drug resistance. Adaptive treatment strategies have been developed as an alternative approach, dynamically adjusting treatment to suppress the growth of treatment-resistant populations and thereby delay, or even prevent, tumor progression. Promising clinical results in prostate cancer indicate the potential to optimize adaptive treatment protocols. Here, we applied deep reinforcement learning (DRL) to guide adaptive drug scheduling and demonstrated that these treatment schedules can outperform the current adaptive protocols in a mathematical model calibrated to prostate cancer dynamics, more than doubling the time to progression. The DRL strategies were robust to patient variability, including both tumor dynamics and clinical monitoring schedules. The DRL framework could produce interpretable, adaptive strategies based on a single tumor burden threshold, replicating and informing optimal treatment strategies. The DRL framework had no knowledge of the underlying mathematical tumor model, demonstrating the capability of DRL to help develop treatment strategies in novel or complex settings. Finally, a proposed five-step pathway, which combined mechanistic modeling with the DRL framework and integrated conventional tools to improve interpretability compared with traditional "black-box" DRL models, could allow translation of this approach to the clinic. Overall, the proposed framework generated personalized treatment schedules that consistently outperformed clinical standard-of-care protocols. SIGNIFICANCE: Generation of interpretable and personalized adaptive treatment schedules using a deep reinforcement framework that interacts with a virtual patient model overcomes the limitations of standardized strategies caused by heterogeneous treatment responses.

Indexed as

Deep LearningPrecision MedicineProstatic NeoplasmsHumansMaleModels, Theoretical

Identifiers

PMID38569183
PMCPMC11148552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.